Syed Rizvi our old CMO has landed on his feet. He, Jen and...

Syed Rizvi our old CMO has landed on his feet. He, Jen and others have helped build our platform and now we get to see where their vision takes us. A month ago he was appointed the new CMO of Poseida Theraputics. Poseida have signed a couple of deals on the back of phase 1 trials, we're in the sweet spot!

https://www.thepharmaletter.com/article/poseida-appoints-new-chief-medical-officer-for-car-t-work

Poseida Therapeutics (Nasdaq: PSTX) has appointed Syed Rizvi as chief medical officer.

Dr Rizvi brings over 20 years of experience across all stages of drug development to the role, including most recently as CMO at Caribou Biosciences (Nasdaq: CRBU).

Prior to this, he held the same role at Chimeric Therapeutics, where he helped build the pipeline in part by licensing programs from universities.

He also led the development of the CAR-T cell therapy Carvykti…


https://www.biospace.com/article/roche-grasps-at-alzheimer-s-and-goes-big-on-blood-cancers-with-poseida/

In 2022 Poseida collaborated with Roche, $110 mill up front and net sales milestones and other payments up to $6 billion in total.

The two companies will also collaborate on a research program to create and develop next-generation allogeneic CAR-T therapies, which Roche may option. Roche is paying Poseida $110 million upfront and up to $110 million in near-term milestones and other payments. Poseida is also eligible for research, development, launch, net sales milestones and other payments up to $6 billion in total, in addition to tiered net sales royalties into the low double digits.

https://www.biospace.com/article/astellas-inks-second-car-t-agreement-with-poseida-to-develop-convertible-cancer-therapies/

Last night Poseida entered into a collaboration and licensing agreement Astellas Pharma to develop novel CAR-T therapies for solid tumors.

Under the deal, Astellas will pay an upfront fee of $50 million and has pledged up to $550 million in potential development, sales and other contingent payments. Poseida will also be eligible for up to low-double digit tiered royalties on net sales. Astellas will conduct the transaction through its subsidiary Xyphos Biosciences.